BOBBI HULLUM: Open Payments
NPI 1861148454 · NEW CASTLE, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,976 in 51 payments from 13 companies in 2025. Trend: 2023 $1,863 · 2024 $3,294 · 2025 $2,976
Consulting: $1,861Food & beverage: $1,088Education: $28
| Company | Payments | Amount |
|---|---|---|
| Calliditas Therapeutics US Inc. | 8 | $2,007 |
| Aurinia Pharma U.S., Inc. | 3 | $157 |
| Bayer Healthcare Pharmaceuticals Inc. | 9 | $155 |
| AstraZeneca Pharmaceuticals LP | 6 | $102 |
| Vifor Pharma, Inc. | 4 | $89 |
| Novartis Pharmaceuticals Corporation | 4 | $83 |
| Otsuka America Pharmaceutical, Inc. | 4 | $82 |
| Novo Nordisk Inc | 3 | $73 |
| Ardelyx, Inc. | 3 | $72 |
| Amgen Inc. | 3 | $58 |
Products named: TARPEYO, LUPKYNIS, Kerendia, FARXIGA, Veltassa, JYNARQUE, IBSRELA, Fabhalta.
Industry payments across PA — which companies pay providers there.
